Changes in cartilage proteoglycan aggrecan after intra-articular injection of interleukin-1 in rabbits: Studies of synovial fluid and articular cartilage

Annals of the Rheumatic Diseases

Volumn 55, Issue 8, 1996, Pages 525-534

  Lundberg, Claes ^a   Åsberg, Inger ^b   Lonescu, Mirela ^c   Reiner, Agnes ^a   Smedegård, Göran ^a   Robin Poole, A ^b  

^a PFIZER INC   (United States)

^b SHRINERS HOSPITAL FOR CHILDREN   (Canada)

^c MCGILL UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

AGGRECAN; INTERLEUKIN 1ALPHA;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; ARTICULAR CARTILAGE; CONTROLLED STUDY; IMMUNOASSAY; INTRAARTICULAR DRUG ADMINISTRATION; PRIORITY JOURNAL; PROTEOGLYCAN SYNTHESIS; RABBIT;

EID: 0029892476     PISSN: 00034967     EISSN: None     Source Type: Journal    
DOI: 10.1136/ard.55.8.525     Document Type: Article

References (36)

1. Pools A R. Cartilage in health and disease. In: McCarty D J, Koopman V J, eds. Anhritis and allied conditions. A textbook of rheumatology. 12th ed. Philadelphia: Lea and Febiger, 1993; 279-333.
2. Heinegård D, Oldberg A. Structure and biology of cartilage and bone matrix non-collagenous macromolecules. FASEB J 1989; 3: 2042-51.
3. Doege K J, Sasaki M, Kimura T, Yamada Y. Complete coding sequence and deduced primary structure of the human cartilage large aggregating proteoglycan aggrecan. Human-specific repeats and additional alternatively spliced forms. JBiolChem 1991; 266: 894-902.
4. Doege K, Sasaki M, Horigan E, Hassell J R, Yamada Y. Complete primary structure of the rat cartilage proteoglycan core protein deduced from cDNA clones. J BiolChem 1987; 262: 17757-67.
5. Giant T T, Mikecz K, Roughley P J, Buzas E, Poole A R. Age-related changes in protein-related epitopes of human articular-cartilage proteoglycans. Biochem J 1986; 236: 71-5.
6. Rizkalla G, Reiner A, Bogoch E, Poole A R. Studies of the articular cartilage proteoglycan aggrecan in health and osteoarthritis. Evidence for molecular heterogeneity and extensive molecular changes in disease. JClin Invest 1992; 90: 2268-77.
7. Franzen A, Inerot S, Bejderuf S O, Heinegârd D. Variations in the composition of bovine hip articular cartilage with distance from the articular surface. Biochem J 1981; 195: 535-43.
8. Bayliss M T, AH S Y. Age-related changes in the composition and structure of human articular cartilage proteoglycans. Biochem J 1978; 176: 683-93.
9. Webber C, Giant T T, Roughley P J, Poole A R. The identification and characterization of two populations of aggregating proteoglycans of high buoyant density isolated from post-natal human articular cartilages of different ages. Biochem J 1987; 248: 735-40.
10. Sandy J D, Neame P ], Boynton R E, Flannery C R. Catabolism of aggrecan in cartilage expiants. Identification of a major cleavage site within the interglobular domain. JBiolChem 1991; 266: 8683-5.
11. Loulakis P, Shrikharde A, Davis G, Maniglia C A. N-terminal sequence of proteoglycan fragments isolated from medium of interleukin-1 treated articular-cartilage cultures. Putative site(s) of enzymic cleavage. Biochem J 1992; 284: 589-93.
12. Sandy J D, Flannery C R, Neame P J, Lohmander L S. The structure of aggrecan-fragments in human synovial fluid. Evidence for the involvement in osteoarthritis of a novelproteinase which cleaves the Glu 373-Ala 374 bond of the interglobular domain. J Clin Invest 1992; 89: 1512-6.
13. Pettipher E R, Higgs G A, Henderson B. Interleukin 1 induces leukocyte infiltration and cartilage proteoglycan degradation in synovial joint. Proc Natl Acad Sei USA 1986;83:8749-53.
14. Pettipher E R, Henderson B, Hardingham T, Ratcliffe A. Cartilage proteoglycan depletion in acute and chronic antigen-induced arthritis. Arthritis Rheum 1989; 32: 601-7.
15. van de Loo A A J, van den Berg V B. Effects of murine recombinant interleukin-1 on synovial joints in mice: measurement of patellar cartilage metabolism and joint inflammation. Ann Rheum Dis 1989; 49: 238-45.
16. Chandrasekhar S, Harvey A K, Hrubey P S. Intra-articular administration of interleukin-1 causes prolonged suppression of cartilage proteoglycan synthesis. Matrix 1992; 11: 1-10.
17. van de Loo F A J, Arntz O J, Ottemess I G, van den Berg W. Protection against cartilage proteoglycan synthesis inhibition by anti-interleukin-1 antibodies in experimental arthritis. J Rheumata! 1992; 19: 348-56.
18. Witter J, Roughley P J, Webber C, Roberts N, Keystone E, Poole A R. The immunological detection and characterization of cartilage proteoglycan degradation products in synovial fluids of patients with arthritis. Arthritis Rheum 1987; 30: 519-26.
19. Poole A R, lonescu M, Swan A, Dieppe P. Changes in cartilage metabolism in arthritis are reflected by altered serum and synovial fluid levels of the cartilage proteoglycan aggrecan: implications for pathogenesis. J Clin Invest 1994; 94: 25-33.
20. Farndale R W, Buttle D J, Barrett A J. Improved quantitation and discrimination of sulphated glycosaminoglycans by use of dimethylmethylene blue. Biodiim BiophysAcm 1986; 883: 173-7.
21. Poolc A R, Reiner A, Roughley P J, Champion B. Rabbit antibodies to degraded and intact glycosaminoglycans which are naturally occurring and present in arthritic rabbits. JBiolChcm 1985; 260: 6025.
22. Mankin H J, Lipiello L. Biochemical and metabolic abnormalities in articular cartilage from osteoarthritic human laps. J Bone Joint Surg Am 1970; 52: 424-34.
23. Thompson R, Oegema T. Metabolic activity of articular cartilage in osteoarthritis. J Bone Joint Surg Am 1979; 61: 407-16.
24. Tyler J A. Articular cartilage cultured with catabolin (pig interleukin 1) synthesizes a decreased number of proteoglycan molecules. Biochem J1985; 227: 869-78.
25. Arner E C, Pratta M A. Independent effects of interleukin-1 on proteoglycan breakdown, proteoglycan synthesis and prostaglandin E2 release from cartilage in organ culture. Arthritis Rheum 1989; 32: 288-97.
26. McDevitt C, Gilbertson E, Muir H. An experimental model of osteoarthritis: early morphological and biochemical changes. J Bone Joint Surg 1977; 59-B: 24-35.
27. McDevitt C, Muir H. Biochemical changes in the cartilage of the knee in experimental and natural osteoarthrosis in the dog. J Bone Joint Surg 1976; 58-B: 94-101.
28. Brandt K D. Enhanced extractability of articular cartilage proteoglycans in osteoarthritis. Biochem J 1974; 143: 475-8.
29. Schünke M, Tillmann B, Brück M, Müller-Ruchholtz W. j Morphologie characteristics of developing osteoarthritis lesions in the knee cartilage of STR/IN mice. Arthritis Rheum 1988; 31: 898-905.
30. van Beuningen H M, Amtz O J, van den Berg W B. In vivo effects of interleukin-1 on articular cartilage. Prolongation of proteoglycan metabolic disturbances in old mice Arthritis Rheum 1991; 34: 606-15.
31. Dean D D, Martel-Pelletier J, Pelletier J-P, Howell D S, Voessner J F. Evidence for metalloproteinase-inhibitor imbalance in human osteoarthritic cartilage. J Clin Invest 1989; 84: 678-85.
32. RatcliSe A, Doherty M, Maini R N, Hardingham T E. Increased concentrations of proteoglycan components in the synovial fluids of patients with acute but not chronic joint disease. Ann Rheum Dis 1988; 47: 826-32.
33. Saxne T, Heinegård D. Synovial fluid analysis of two groups of proteoglycan epitopes distinguishes early and later cartilage lesions. Arthritis Rheum 1992; 35: 385-90.
34. Mansson B, Carey D, Alini M, et al. Cartilage and bone metabolism in rheumatoid arthritis. Differences between rapid and slow progression of disease identified by serum markers of cartilage metabolism. J Clin Invest 1995; 95: 1071-7.
35. Poole A R. Immunochemical markers of joint inflammation, skeletal damage and repair: where are we now? Ann Rheum Dis 1994; 53: 3-5.
36. Poole A R, Dieppe P D. Biological markers in rheumatoid arthritis. Semin Arthritis Rheum 1994; 23 (suppl 2): 17-31.